(Q37765470)

22 August 2017

1 reference

title

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. (English)

1 reference

22 August 2017

2

Fabrice André

0 references

Jean-Charles Soria

series ordinal

3

object named as

Jean-Charles Soria

0 references

author name string

Charles Ferté

series ordinal

1

1 reference

PubMed ID

20551944

22 August 2017

language of work or name

English

0 references

publication date

15 June 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

7

1 reference

22 August 2017

367-380

1 reference

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Proliferation marker Ki-67 in early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The genetic attributable risk of breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

First-generation genomic tests for breast cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

A gene-expression signature as a predictor of survival in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Gene expression predictors in breast cancer: current status, limitations and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Molecular predictive and prognostic markers in non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

A five-gene signature and clinical outcome in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

KRAS mutations in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Molecular origins of cancer: Molecular basis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Genetic prognostic and predictive markers in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Barriers to Integrating Gene Profiling for Stage II Colon Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Are RAS mutations predictive markers of resistance to standard chemotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Moyamoya disease and moyamoya syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Genetic instability in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prostate cancer genomics: towards a new understanding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Recurrent gene fusions in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

TMPRSS2-ERG and PTEN loss in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Genomic approaches to outcome prediction in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Biomolecular markers of outcome prediction in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The polycomb group protein EZH2 is involved in progression of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Molecular classification of neoplasms of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Advanced Pancreatic Ductal Cancer: Fibrotic Focus and β-Catenin Expression Correlate With Outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

The biology of ovarian cancer: new opportunities for translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Mismatch repair and treatment resistance in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

31 March 2020

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

What should physicians look for in evaluating prognostic gene-expression signatures?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.84

Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications

31 March 2020

1 reference

12 December 2020

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

1 reference

12 December 2020

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

12 December 2020

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung

1 reference

12 December 2020

BRAFMutation in Metastatic Colorectal Cancer

1 reference

12 December 2020

10.1038/NRCLINONC.2010.84

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20551944